Compare ABAT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | EOLS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.9M | 444.0M |
| IPO Year | N/A | 2018 |
| Metric | ABAT | EOLS |
|---|---|---|
| Price | $3.98 | $6.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 5.6M | 854.3K |
| Earning Date | 02-13-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,025,853.00 | ★ $285,823,000.00 |
| Revenue This Year | $145.40 | $14.24 |
| Revenue Next Year | N/A | $21.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 821.40 | 15.10 |
| 52 Week Low | $0.86 | $5.71 |
| 52 Week High | $11.49 | $17.12 |
| Indicator | ABAT | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 47.29 |
| Support Level | $3.61 | $7.01 |
| Resistance Level | $4.43 | $7.25 |
| Average True Range (ATR) | 0.38 | 0.24 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 42.35 | 18.49 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.